OGN vs PFE vs VTRS vs ABBV vs HLN

For growth investors, AbbVie Inc.

(ABBV) is the stronger pick with 8. 6% revenue growth year-over-year, versus -4. 0% for Haleon plc (HLN). Organon & Co. (OGN) offers the better valuation at 18. 5x trailing P/E (3. 9x forward), making it the more compelling value choice. Analysts rate AbbVie Inc. (ABBV) a "Buy" — based on 41 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Organon & Co.

(OGN) is the cheapest at 18. 5x versus AbbVie Inc. at 85. 5x. On forward P/E, Organon & Co. is actually cheaper at 3. 9x.

Over the past 5 years, AbbVie Inc.

(ABBV) delivered a total return of +101. 3%, compared to -47. 1% for Organon & Co. (OGN). Over 10 years, the gap is even starker: ABBV returned +295. 5% versus VTRS's -51. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Haleon plc (HLN) is the lower-risk stock at 0.

06β versus Organon & Co. 's 1. 10β — meaning OGN is approximately 1704% more volatile than HLN relative to the S&P 500. On balance sheet safety, Haleon plc (HLN) carries a lower debt/equity ratio of 52% versus 100% for Viatris Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), AbbVie Inc.

(ABBV) is pulling ahead at 8. 6% versus -4. 0% for Haleon plc (HLN). On earnings-per-share growth, the picture is similar: Haleon plc grew EPS 12. 5% year-over-year, compared to -466. 0% for Viatris Inc.. Over a 3-year CAGR, ABBV leads at 1. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Haleon plc (HLN) is the more profitable company, earning 15.

1% net margin versus -24. 6% for Viatris Inc. — meaning it keeps 15. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ABBV leads at 32. 8% versus -18. 6% for VTRS. At the gross margin level — before operating expenses — PFE leads at 70. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Organon & Co.

(OGN) trades at 3. 9x forward P/E versus 22. 2x for Haleon plc — 18. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ABBV: 26. 6% to $256. 64.

In this comparison, PFE (6.

5% yield), ABBV (3. 2% yield), VTRS (2. 8% yield), HLN (1. 9% yield) pay a dividend. OGN does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Haleon plc (HLN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

06), 1. 9% yield). Both have compounded well over 10 years (HLN: +31. 7%, OGN: -47. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: OGN is a small-cap quality compounder stock; PFE is a mid-cap income-oriented stock; VTRS is a mid-cap quality compounder stock; ABBV is a large-cap income-oriented stock; HLN is a mid-cap quality compounder stock. PFE, VTRS, ABBV, HLN pay a dividend while OGN does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.